Eli Lilly and Co. has downplayed for about 10 years the risks associated with Zyprexa, which treats schizophrenia, The New York Times said on its Web site Sunday, citing internal documents from the drug maker and e-mail messages of its managers.
The documents, obtained from a lawyer for mentally ill patients, show Lilly executives kept data from doctors about the drug’s tendencies to promote obesity and boost blood sugar, the newspaper said.